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berculosis and TNF
tagonists -- What are we
issing?
berculose e antagonistas do FNT -- onde
tamos a falhar?
ar  Editor,
2012  Portugal  had  a  tuberculosis  incidence  of
.6/100,000  inhabitants  (2286  new  cases,  942  of  which
1
reviewed  all  cases  of  tuberculosis  between  03/2010  and
02/2012  in  Portugal’s  northern  region,  identifying  those  who
developed  the  disease  while  on  anti-TNF-  therapy.  In  this
region  there  are  both  clinical  notiﬁcation  of  all  tuberculosis
cases  and  laboratory  notiﬁcation  of  conﬁrmed  cases  (which
allowed  for  the  identiﬁcation  of  all  patients).  Demographic,
epidemiological  and  clinical  data  was  obtained  by  consulting
epidemiological  research  studies  and  clinical  records.
In  the  period  studied,  1834  cases  of  tuberculosis  were
diagnosed  in  the  region,  ﬁve  of  which  were  receiving  anti-
TNF-  therapy  (Table  1).
All  these  5  cases  had  intestinal  disease  (4  had  Crohn’s
disease)  of  an  average  duration  of  18.2  years  (minimum  7se  
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there  reported  in  the  northern  region). A  recent  retro-
ective  study  in  Portugal  identiﬁed,  from  2001  to  2012,  25
ses  of  tuberculosis  out  of  765  patients  under  anti-TNF
7/100,000  patient-years).2
Treatment  with  tumor  necrosis  factor  antagonists  (anti-
F)  is  associated  with  an  elevated  risk  for  development
tuberculosis  mostly  due  to  reactivation  of  latent  tuber-
losis  infection.  Since  2006,  national  guidelines  advise
erculosis  screening  for  all  candidates  for  anti-TNF
rapy  including  chest  X  ray,  tuberculin  skin  test  (TST)
d  Interferon-Gamma  Release  Assay  (IGRA)  and  treatment
uld  be  offered  to  every  patient  with  evidence  of  LTBI,
vided  major  toxicity  is  excluded.3
Worldwide,  the  application  of  tuberculosis  screening
idelines  in  these  patients  has  been  related  to  a  decrease
tuberculosis  within  this  group.4,5
In  order  to  understand  the  pitfalls  that  can  still  lead
the  development  of  tuberculosis  in  these  patients,  we
able  1  Patient  data.
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ximum  30).  None  of  the  patients  had  known  exposure  to
erculosis,  3  patients  underwent  screening  with  TST  but
RA  was  never  used.  One  patient  was  diagnosed  with  latent
ection  based  on  a  TST  of  8  mm  induration  and  started  iso-
zid  but  it  was  suspended  15  days  later  due  to  liver  toxicity
d  anti-TNF-  was  started.  Patients  developed  tuberculosis
tween  3  and  24  months  on  therapy.
In  none  of  the  cases  was  screening  performed  according
the  published  guidelines,  it  was  either  absent  or  incom-
te.  Even  though  they  represent  a  small  fraction  of  TB
gnosis,  the  incidence  in  this  group  is  signiﬁcantly  higher2
d  a  methodical  screening  and  follow  up  while  on  biological
rapy  should  be  our  goal.  This  is  particularly  important  in  a
untry  like  ours  which  has  an  intermediate  incidence  of  TB.
The  fact  that  all  TB  cases  occurred  in  patients  being
ated  for  inﬂammatory  bowel  disorders  may  represent  a
k  of  awareness  of  tuberculosis  and  of  the  guidelines  by
 clinicians  treating  these  patients.Pulmonary  Pulmonary  Pulmonary,
Pleural
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Rns
st54  LETTERS  TO  THE  EDITO
References
1. Duarte R, Diniz A. Programa Nacional de Luta Contra a Tuber-
culose. In: Ponto da Situac¸ão Epidemiológica e de Desempenho.
Marc¸o 2013. http://www.dgs.pt/
2. Abreu C, Magro F, Santos-Antunes J, Pilão A, Rodrigues-
Pinto E, Bernardes J, et al. Tuberculosis in anti-TNF-
treated patients remains a problem in countries with an
intermediate incidence: analysis of 25 patients matched
with a control population. J Crohns Colitis. 2013;7:e486--92,
http://dx.doi.org/10.1016/j.crohns.2013.03.004.
3. Fonseca JE, Lucas H, Canhão H, Duarte R, José Santos M, Villar M,
et al. Recommendations for the diagnosis and treatment of latent
and active tuberculosis in inﬂammatory joint diseases candidates
for therapy with tumor necrosis factor alpha inhibitors -- March
2008 update. Rev Port Pneumol. 2008;XIV:271--83.
4. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D,
Pascual-Goméz E, Mola EM, et al. Effectiveness of recommenda-
tions to prevent reactivation of latent tuberculosis infection in
patients treated with tumor necrosis factor antagonists. Arthritis
Rheum. 2005;52:1766--72.
5. Nacci F, Matucci-Cerinic M. Tuberculosis and other infectio
in the anti-tumour necrosis factor-alpha (anti-TNF-a) era. Be
Pract Res Clin Rheumatol. 2011;25:375--88.
C.  Ribeiroa,∗,  A.M.  Correiab,  R.  Duartec,d
a Centro  Hospitalar  de  Vila  Nova  de  Gaia,  Vila  Nova  de
Gaia,  Portugal
b Public  Health  Department,  Administrac¸ão Regional  de
Saúde  do  Norte,  Porto,  Portugal
c Centro  de  Referência  Regional  para  a  Tuberculose
Multirresistente  da  Região  de  Saúde  do  Norte,  Vila  Nova
de  Gaia,  Portugal
d Centro  de  Diagnóstico  Pneumológico  de  Vila  Nova  de
Gaia,  Vila  Nova  de  Gaia,  Portugal
∗Corresponding  author.
http://dx.doi.org/10.1016/j.rppneu.2013.09.002
